Comprehensive Analysis of the Anatomic Pathology Market

Global anatomic pathology market is anticipated to grow at a CAGR of 8.5% during the forecast period (2024–2031). The market growth is attributed to the rising incidence, and prevalence of chronic diseases, such as liver and kidney disease, cancer, and infectious disease. Cancer cases are escalating rapidly across the globe, with the maximum patients suffering from lung, prostate, colorectal, and breast cancer.  

Anatomic pathology products and services play an important role in oncology drug trials. They are employed to gather quantitative data, detect pharmacodynamics markers, and identify morphological structures. However, the availability of refurbished anatomic pathology instruments is one of the major challenges for market growth. 

Browse the full report description of “Anatomic Pathology Market Size, Share & Trends Analysis Report by Products & Services (Consumables, Services, and Instruments) by End-Users (Hospitals, Clinical Laboratory, and Others), by Application (Disease Diagnosis, and Drug Discovery) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/anatomic-pathology-market-size

North America is estimated to hold a substantial share of the global anatomic pathology market. This is owing to the rising investment by government and academic research centers in diagnostic research and the incidence of lung cancer and other chronic disease. Additionally, factors such as the growing elderly population and increasing focus on biomarker research facilitate market expansion in this region. This market is further boosted by the presence of major players such as Abbott Laboratories in the region. Furthermore, the adoption of the Affordable Care Act and Healthcare reforms are expected to support the growth of the market during the forecast period.  

Recent Developments

• In July 2023, PathAI a provider of AI-powered pathology tools, announced the availability of AIM-HER2 breast cancer for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive Multiple Instance Learning (aMIL) heatmaps to visualize the slide features driving the algorithm’s predicted score. 

• In September 2022, Epredia’s parent company, PHC Holdings Corporation acquired anatomical pathology suppliers Micron Microtech France and Laurypath in a strategic expansion of Epredia's presence in Europe.

Market Coverage  

· The market number available for 2023-2031 

· Base year: 2023 

· Forecast period: 2024-2031 

· Segment Covered- 

o By Products and Services

o By Application

o By End-user 

· Regions Covered- 

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World

• Competitive Landscape: Danaher Corp., Agilent Technologies Inc., Abcam Plc, Abbott Laboratories, and F. Hoffman La Roche among others.

Key questions addressed by the report 

• What is the market's growth rate? 
• Which segment and region dominate the market in the base year? 
• Which segment and region will project the fastest growth in the market? 
• Who is the leader in the market? 
• How are players addressing challenges to sustain growth? 
• Where is the investment opportunity? 

Global Anatomic Pathology Market Report Segment 

By Products and services

• Consumables
• Services 
• Instruments

By End-user

• Hospitals
• Clinical Laboratory 
• Others (Research Institutes)

By Application

• Disease Diagnosis
• Drug Discovery

Global Anatomic Pathology Market Report Segment by Region 

North America 

· United States 

· Canada 

Europe 

· UK 

· Germany 

· Italy 

· Spain 

· France 

· Rest of Europe 

Asia-Pacific 

· China 

· India 

· Japan 

· South Korea 

· Rest of Asia-Pacific 

Rest of the World 

· Latin America

· Middle East and Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/anatomic-pathology-market-size